NCT06271486

Brief Summary

Lumbar puncture (LP), often known as a "spinal tap," is a standard medical technique pioneered in the late 1900s by Heinrich Quincke. It involves the retrieval and analysis of cerebrospinal fluid (CSF) from the spinal cord, serving as the benchmark for diagnosing conditions like subarachnoid hemorrhage, meningitis, and specific neurological conditions. Pregabalin, an anticonvulsant medicine that blocks calcium entry, is used to treat a variety of diseases. It has been used to relieve pain in a variety of patient groups, including those with chronic pain, epilepsy, and anxiety disorders

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Feb 2024

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 14, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 21, 2024

Completed
7 days until next milestone

Study Start

First participant enrolled

February 28, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 15, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 15, 2024

Completed
Last Updated

June 18, 2025

Status Verified

June 1, 2025

Enrollment Period

6 months

First QC Date

February 14, 2024

Last Update Submit

June 14, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • the incidence of complete relief

    The incidence of complete relief, as reflected in the success rate of the intervention at 48 hours.

    48 hours

Secondary Outcomes (1)

  • The intensity of the headache

    48 hours

Study Arms (3)

Group A (pregabalin group)

ACTIVE COMPARATOR

Received oral pregabalin treatment administered at 150 mg daily, with 75 mg given every 12 hours.

Drug: Pregabalin 75mg

Group B (EBP group)

ACTIVE COMPARATOR

Received active therapy in the form of an EBP and Group C (control group) received conservative treatment.

Biological: An epidural blood patch (EBP)

Group C (the control group)

ACTIVE COMPARATOR

received conservative treatment.

Combination Product: conservative treatment.

Interventions

Group A (pregabalin group) received oral pregabalin treatment administered at 150 mg daily, with 75 mg given every 12 hours.

Group A (pregabalin group)

Group B (EBP group) received active therapy in the form of an EBP

Group B (EBP group)
conservative treatment.COMBINATION_PRODUCT

Group C (control group) received conservative treatment providing recommendations to the patients, including 24 hours of bed rest, stool softener, and consuming a minimum of 2.0 liters of fluid daily. Analgesics were permitted for pain relief depending on the patient's disease status.

Group C (the control group)

Eligibility Criteria

Age21 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age from 21 to 65 years old,
  • both genders,
  • confirmed diagnosis of postdural puncture headache (PDPH)

You may not qualify if:

  • patient refusal
  • known allergy to the drug used in the study
  • patients with a history of convulsions
  • chronic headaches
  • contraindications to regional anesthesia (such as local infection and coagulation abnormalities).
  • Clinical indications of elevated intracranial pressure or associated risk factors
  • Deteriorated patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Neveen Kohaf

Tanta, 11865, Egypt

Location

MeSH Terms

Conditions

Post-Dural Puncture Headache

Interventions

PregabalinConservative Treatment

Condition Hierarchy (Ancestors)

Headache Disorders, SecondaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

gamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsAmino AcidsAmino Acids, Peptides, and ProteinsTherapeutics

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Clinical Pharmacy

Study Record Dates

First Submitted

February 14, 2024

First Posted

February 21, 2024

Study Start

February 28, 2024

Primary Completion

August 15, 2024

Study Completion

August 15, 2024

Last Updated

June 18, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will share

Data will be shared upon reasonable request from corresponding author

Shared Documents
STUDY PROTOCOL, SAP, ICF

Locations